able to communicate, Adult patients (> 18 years of age) undergoing palliative care (defined by the WHO as active, and with a functional central venous line with reflux, comprehensive care given to patients whose condition does not respond to curative treatment) of their disease, presenting spontaneous pain with a numerical scale greater than 3 or paracetamol as part of their usual treatment.
Conditions
Brief summary
- Measurement of paracetamolemia to determine AUC0-t, AUC0-, Cmax , Vd and t1/2 for each mode of administration for the same patient, and generation of pharmacokinetic curves.
Detailed description
- Pain assessment using a digital scale, - Skin monitoring and tolerance assessment throughout administration and protocol completion (D0 to D30), - Safety criterion: systematic collection of adverse events of any grade (CTCAE scale) from the signing of consent to D30 (minimum follow-up period for drug research).
Interventions
DRUGsolution pour perfusion
Sponsors
Centre Hospitalier Universitaire De Caen Normandie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Measurement of paracetamolemia to determine AUC0-t, AUC0-, Cmax , Vd and t1/2 for each mode of administration for the same patient, and generation of pharmacokinetic curves. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Pain assessment using a digital scale, - Skin monitoring and tolerance assessment throughout administration and protocol completion (D0 to D30), - Safety criterion: systematic collection of adverse events of any grade (CTCAE scale) from the signing of consent to D30 (minimum follow-up period for drug research). | — |
Countries
France
Outcome results
None listed